GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today
announced that the Company will hold a conference call on November 13,
2008 at 3 PM CET/9 AM ET to discuss its financial results for the third
quarter of 2008 and provide a corporate update. The results will be
published on November 13 in advance of the conference call.
Participants may listen via live webcast, accessible through the GPC
Biotech Web site at www.gpc-biotech.com
or via telephone. A replay will be available on the Web site following
the live event. The call will be conducted in English.
The dial-in numbers for the call are as follows:
Participants in Europe: 0049(0)89 9982 99911 or 0044(0)20 7806 1956
Participants in the U.S.: 1-212-444-0413
Please dial in 10 minutes before the beginning of the call.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on
anticancer drugs. GPC Biotech's lead product candidate is satraplatin,
an oral platinum compound. The Company has various anti-cancer programs
in research and development that leverage its expertise in kinase
inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany) and has a wholly owned U.S. subsidiary in Princeton, New
Jersey. For additional information, please visit GPC Biotech's Web site
at www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or
implied by such forward-looking statements. Actual results could differ
materially depending on a number of factors, and we caution investors
not to place undue reliance on the forward-looking statements contained
in this press release. We direct you to GPC Biotech’s
Annual Report on Form 20-F for the fiscal year ended December 31, 2007
and other reports filed with the U.S. Securities and Exchange Commission
for additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they are
made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
GPC Biotech AG
Investor Relations & Corporate Communications
+49
(0)89 8565-2693
ir@gpc-biotech.com
or
In
the U.S.:
Laurie Doyle, +1 609-524-5884
Director, Investor
Relations & Corporate Communications
usinvestors@gpc-biotech.com
or
Additional
media contacts for Europe:
MC Services AG
Raimund Gabriel,
+49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
Hilda
Juhasz, +49 (0) 89 210 228 0
hilda.juhasz@mc-services.eu
or
Additional
investor contact for Europe:
Trout International LLC
Lauren
Rigg, +44 207 936 9325
Vice President
lrigg@troutgroup.com
